Stockscreener 앱 받기
0.9386
1.20%
-0.0114
전일 마감가:
$0.95
열려 있는:
$0.96
하루 거래량:
30,626
Relative Volume:
0.01
시가총액:
$7.86M
수익:
$1.52M
순이익/손실:
$-13.97M
주가수익비율:
-0.3077
EPS:
-3.05
순현금흐름:
$-13.29M
1주 성능:
+6.65%
1개월 성능:
-8.87%
6개월 성능:
+16.89%
1년 성능:
-27.80%
1일 변동 폭
$0.9202
$0.96
1주일 범위
$0.88
$1.03
52주 변동 폭
$0.55
$3.06
Predictive Oncology Inc Stock (POAI) Company Profile
명칭
Predictive Oncology Inc
전화
412-432-1500
주소
91 43RD STREET, PITTSBURGH, MN
POAI을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
POAI
Predictive Oncology Inc
|
0.9386 | 7.86M | 1.52M | -13.97M | -13.29M | -3.05 |
|
ISRG
Intuitive Surgical Inc
|
557.08 | 197.97B | 8.71B | 2.48B | 1.75B | 6.82 |
|
BDX
Becton Dickinson Co
|
173.45 | 49.82B | 20.87B | 1.50B | 2.59B | 5.24 |
|
ALC
Alcon Inc
|
87.79 | 42.51B | 9.93B | 1.12B | 1.58B | 2.25 |
|
RMD
Resmed Inc
|
252.20 | 35.89B | 5.02B | 1.31B | 1.56B | 8.91 |
|
BAX
Baxter International Inc
|
30.26 | 15.65B | 11.89B | -560.00M | 191.00M | -1.10 |
Predictive Oncology Inc Stock (POAI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-19 | 개시 | H.C. Wainwright | Buy |
Predictive Oncology Inc 주식(POAI)의 최신 뉴스
Predictive Oncology (NASDAQ:POAI) Stock Price Crosses Below 200 Day Moving Average – What’s Next? - Defense World
Major AI Breakthrough in Cancer Research: Leading Pharma Companies Unite in Revolutionary Oncology Initiative - Stock Titan
SEC Form 424B5 filed by Predictive Oncology Inc. - Quantisnow
'It's not something you choose to do, it's something you have to do': CEO & artist shares story - WTAE
Predictive Oncology (NASDAQ:POAI) Stock Crosses Below 200 Day Moving Average – Time to Sell? - Defense World
Court Denies Renovaro Motion for an Expedited Trial in July - GlobeNewswire
Predictive Oncology says court denies Renovaro motion for expedited trial - TipRanks
Predictive Oncology to defend against Renovaro’s claims in court By Investing.com - Investing.com Canada
Predictive Oncology (POAI) Addresses Legal Dispute with Renovaro - GuruFocus
Predictive Oncology to defend against Renovaro’s claims in court - Investing.com Australia
Court Denies Renovaro Motion for an Expedited Trial in July | POAI Stock News - GuruFocus
Delaware Court Rejects Renovaro's Rush to Trial Against Predictive Oncology, Cites Critical Delays - Stock Titan
Renovaro Inc. Accelerates 2025 Lawsuit to Force Predictive Oncology Merger - MSN
Predictive Oncology Stock Hits 1-Month Low Amid Renovaro Legal Clash, But Retail Leans Bullish By Stocktwits - Investing.com India
UPDATERenovaro Inc. Announces Expedited Trial for 2025 Lawsui - GuruFocus
Predictive Oncology (POAI) Advances AI-Driven Cancer Drug Discov - GuruFocus
Renovaro Sues Predictive Oncology (POAI) Over Merger Agreement D - GuruFocus
Renovaro Gets Expedited Trial in Predictive Oncology Merger Dispute - marketscreener.com
Renovaro Inc. Announces Expedited Trail for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology - The Manila Times
Renovaro Inc. Announces Expedited Trail for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology | RENB Stock News - GuruFocus
Renovaro Inc. Secures Ruling to Expedite Trial Against Predictive Oncology Over Breach of Merger Agreement - Nasdaq
Renovaro Inc. Announces Expedited Trail for 2025 Lawsuit to - GlobeNewswire
Court Fast-Tracks Renovaro's Lawsuit to Force Predictive Oncology Merger After 50% Stock Jump Drama - Stock Titan
AI Meets Genomics: Predictive Oncology Breakthrough Coincides with Regeneron's $256M 23andMe Acquisition | POAI Stock News - GuruFocus
Predictive Oncology harnesses AI for drug discovery - Investing.com
Predictive Oncology moves to leverage biobank using AI - TipRanks
Predictive Oncology harnesses AI for drug discovery By Investing.com - Investing.com Nigeria
Predictive Oncology Inc. Advances AI-Driven Drug Discovery with Extensive Biobank of Tumor Samples - Nasdaq
AI Meets Genomics: Predictive Oncology Breakthrough Coincides with Regeneron's $256M 23andMe Acquisition - GlobeNewswire
Major AI Breakthrough: How 150,000 Live Tumor Samples Are Revolutionizing Cancer Drug Discovery - Stock Titan
Predictive Oncology issued shareholder letter - TipRanks
Predictive Oncology (POAI) Showcases Recent Achievements and Future Plans | POAI Stock News - GuruFocus
Predictive Oncology Inc. Issues Shareholder Letter Titled, - GuruFocus
Predictive Oncology Expands AI-Driven Platform to Include Biomarker Discovery and Drug Repurposing for Precision Oncology - Nasdaq
Predictive Oncology Inc. Issues Shareholder Letter Titled, "Revolutionizing Medicine: ... - Bluefield Daily Telegraph
Revolutionary AI Platform Expands into $14.5B Biomarker Market with Game-Changing Cancer Prediction Technology - Stock Titan
Predictive Oncology reports loss, but has "meaningfully expanded the potential" of its AI platform - The Business Journals
Predictive Oncology Inc. Reports Q1 2025 Earnings - TipRanks
Predictive Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
Predictive Oncology (POAI) Sees Significant Revenue Growth in Q1 2025 | POAI Stock News - GuruFocus
Predictive Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update | POAI Stock News - GuruFocus
Predictive Oncology Reports Q1 2025 Financial Results and Corporate Developments - Nasdaq
Healthcare Diagnostics Sector Witnessing Significant Growth in Artificial Intelligence Based Technologies - GlobeNewswire
Predictive Oncology (POAI) Projected to Post Earnings on Tuesday - Defense World
Head-To-Head Review: Pathfinder Cell Therapy (OTCMKTS:PFND) versus Predictive Oncology (NASDAQ:POAI) - Defense World
Predictive Oncology Inc (POAI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.70%
0.20%
자본화:
|
볼륨(24시간):